At least one minor positive is that the performance shares are unlikely to vest and convert to shares.
Class A requires a 20 day VWAP of $2.00 per share and US$6.6m in revenue for CY17 (no chance)
Class B requires a 20 day VWAP of $2.50 per share and US$6.6m in revenue for CY17 (no chance)
Class C already lapsed
Class D requires US$20m for CY17 (unlikely)
News: M7T Mach7 Technologies to divest its 3D medical operations, page-5
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add M7T (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
0.005(0.93%) |
Mkt cap ! $131.4M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 54.5¢ | 52.5¢ | $105.2K | 198.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48295 | 53.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.5¢ | 30308 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| M7T (ASX) Chart |